Teneliximab
Based on 1 Customer Validation
Teneliximab (BMS-224819) is a chimeric monoclonal antibody, blocks the CD40-CD40L interaction. Teneliximab (BMS-224819) has partial agonist activity resulting in some signaling through CD40 and peripheral B cell depletion.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: ≥99.0%
- CAS No.: 299423-37-3
- Masse moléculaire:146.06 kDa
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Voir tous les produits spécifiques à Isoform TNF Receptor
More
Activité biologique
Human IgG1 kappa
Human
CD40
The effects of Teneliximab (Chi220, BMS-224819) are not mediated solely through deletion of CD20-bearing cells and that the combined therapy did not significantly impair established antiviral immunity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
P25942-1
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG1 kappa
ELISA, FACS, Functional assay
-
Flow Cytometry analysis of Raji cells labelling CD40 (red) with Teneliximab (anti-CD40) (HY-P99321). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG1 kappa (HY-P99001). Black-Unlabelled control, cells without incubation with primary antibody.
Chemical Information
-
CAS No. 299423-37-3
-
Appearance Liquid
-
Masse moléculaire 146.06 kDa
-
Color Colorless to light yellow
-
SMILES
[Teneliximab]
-
Synonyms
BMS 224819; Chi220; Anti-Human CD40 Recombinant Antibody
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (256 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Maria A Argiriadi, et al. CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches. BMC Mol Cell Biol. 2019 Aug 5;20(1):29. [Content Brief]
[2]. Andrew B Adams, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol. 2005 Jan 1;174(1):542-50. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz